Business Insider26d
Buy Rating Affirmed for Protagonist Therapeutics: Innovative Peptide Platform and Promising Pipeline Drive Growth Prospects
which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm’s initial lead product candidates ...
Business Insider26d
Hold Rating Maintained for Protagonist Therapeutics Amid Promising Phase 3 Assets and Limited Financial Upside Due to Licensing Agreements
which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm’s initial lead product candidates ...